CClinicalTrials.gg
CompletedNCT01779674Updated Jan 8, 2014

Atrial Fibrillation/Sinus Rhythm Before and After Cardioversion

An observational study in Atrial Fibrillation, sponsored by RWTH Aachen University. Completed at 1 site in Germany. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2014-01-08.

Sponsored by RWTH Aachen University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25
Ages
18 Years to 90 Years
Sex
All
01

Study summary

This study´s aim is to collect scientific data about patients with atrial inflammation by two principles of sensors measuring congestive heart failure.

02

Conditions studied

  • Atrial Fibrillation

Browse trials for

03

In context

Atrial Fibrillation

3,869 studies on the registry are indexed under Atrial Fibrillation; 923 are open to participants now.

This study's enrollment of 25 is below the median of 300 across 1,362 observational studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

RWTH Aachen University is the lead sponsor of 228 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with atrial fibrillation

Inclusion criteria

  • patients with atrial fibrillation and planned cardioversion
  • male and female patients aged at least 18 years
  • patients being able to understand and to follow the study staff´s instructions
  • signed informed consent

Exclusion criteria

Exclusion Criteria:

  • persons being hosted in an institution by administrative order or court injunction
  • pregnancy or breast feeding
  • persons not being able to consent
  • persons with implanted electronic devices
  • material incompatiblity
  • acute or chronic inflammation of the external or middle ear canal
  • abnormal anatomic ear canal (congenital or pathological)
  • persons in a dependent relationship to the investigator or employment contract
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. scientific data

    Time frame: 1 hour

07

Study locations

1 site
  • Univeristy Hospital Aachen
    Aachen, North Rhine Westfalia 52074, Germany
08

References and documents

Publications

  • Zink MD, Bruser C, Winnersbach P, Napp A, Leonhardt S, Marx N, Schauerte P, Mischke K. Heartbeat Cycle Length Detection by a Ballistocardiographic Sensor in Atrial Fibrillation and Sinus Rhythm. Biomed Res Int. 2015;2015:840356. doi: 10.1155/2015/840356. Epub 2015 Jul 1. PubMed 26229965 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01779674
Lead sponsor
RWTH Aachen University
Responsible party
Sponsor
First posted
Jan 30, 2013
Start date
Aug 2011
Primary completion
Apr 2012
Completion
Apr 2012
Last update
Jan 8, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion